SynAct Pharma publishes Q1 2022 interim report
SynAct Pharma AB (publ) (“SynAct”) today publishes the interim report for the first quarter 2022.“During the first quarter, we made important decisions regarding the continued development of AP1189 and not least secured financing for the next development phase. We have prepared to be able to start important studies in RA shortly, have been active in business development and have prepared for listing of the share on Nasdaq,” said Jeppe Øvlesen, CEO. January – March 2022 · The Group’s net sales amounted to SEK 0 (0) thousand, which is in line with expectations given the phase the